p.22 抽出テキスト

HER2-targeted ther a pies c

Baseline clinical CV assessment , p

, h ysical exam and ECG a r e r ecommended

in all cancer patients scheduled f or ca

f f r diot o xic ther a pies a

Previous CVD

Previous CVD

All other patients

All patients

All patients

All other patients

Previous CVD

All patients

High and very high risk Moderate risk Low risk Other conditions Class IIb Class IIa Class I

Anthracyclines

Fluo r o p y r ymidines

VEGFi

Second- and thi r d-generation BCR-ABL TKI d

BTK inhibitors

PI e

RAF and MEK inhibitors

ICI

Osime r tinib

C AR-T and TIL

R T to a R R v olume including the hea r t

HSCT TTEb Patient risk level NP cTn

Figure 7 Baseline screening recommendations for patients with cancer treated with potentially cardiotoxic drugs. 3D, three-dimensional; ADT, androgen deprivation therapy; AL-CA, amyloid light-chain cardiac amyloidosis; BC, breast cancer; BCR-ABL, breakpoint cluster region-Abelson oncogene locus; BNP, B-type natriuretic peptide; BTK, Bruton tyrosine kinase; CAR-T, chimeric antigen receptor T cell; CDK, cyclin-dependent kinase; CMR, cardiac magnetic resonance; cTn, cardiac troponin; CV, cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram; GLS, global longitudinal strain; HER2, human epidermal receptor 2; HSCT, haematopoietic stem cell transplantation; ICI, immune checkpoint inhibitors; LVEF, left ventricular ejection fraction; MEK, mitogen-activated extracellular signal-regulated kinase; NP, natriuretic peptides (including BNP and NT-proBNP); NT-proBNP, N-terminal pro-B-type natriuretic peptide; PI, proteasome inhibitors; RAF, rapidly accelerated fibrosarcoma; RT, radiotherapy; TIL, tumour-infiltrating lymphocytes; TKI, tyrosine kinase inhibitors; TTE, transthoracic echocardiography; VEGFi, vascular endothelial growth factor inhibitors. aIncluding patients scheduled to receive ADT for prostate cancer, CDK 4/6 inhibitors, endocrine hormone therapy for BC and anaplastic lymphoma kinase inhibitors. bTTE is recommended as the first-line modality for the assessment of cardiac function. 3D echocardiography is recommended to measure LVEF. GLS is recommended in all patients with cancer having echocardiography, if available. CMR should be considered when echocardiography is unavailable or not diagnostic. cBaseline cTn measurement should be considered (Class IIa, Level A) in low- and moderate-risk patients post-anthracycline chemotherapy but prior to starting HER2-targeted therapies. Baseline NP and cTn measurement may be considered (Class IIb, Level C) in low- and moderate-risk patients. dBaseline echocardiography is recommended in patients scheduled to receive dasatinib (Class I, Level C). eNP and cTn measurements are recommended at baseline in patients with AL-CA (Class I, Level B). Downloaded from academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 07 October 2026